---
title: A new path to the clinic using CRISPR-Cas screens and cell panel drug screens in target ID and validation.
---

[![DDW-Logo](https://info.edifydigitalmedia.com/hs-fs/hubfs/DDW-Logo.png?width=239&height=121&name=DDW-Logo.png "DDW-Logo")](https://www.edifydigitalmedia.com/)

![shutterstock\_203004319 horizon banner](https://info.edifydigitalmedia.com/hubfs/shutterstock_203004319%20horizon%20banner.jpg "shutterstock_203004319 horizon banner")

Webinar: A new path to the clinic using CRISPR-Cas screens and cell panel drug screens in target ID and validation

 

 

 

 

*Brought to you by* 

 

![Horizon-Logo-LR](https://info.edifydigitalmedia.com/hs-fs/hubfs/Horizon-Logo-LR.jpg?width=226&name=Horizon-Logo-LR.jpg)

---

 

![Pal-Mander\_speaker\_image\_200px](https://info.edifydigitalmedia.com/hubfs/Pal-Mander_speaker_image_200px.jpg "Pal-Mander_speaker_image_200px")

Navigating from target identification to validation can be a complex and time consuming process, so it makes sense to find the right assays and models to validate or refute a hypothesis ahead of costly clinical trials. CRISPR-Cas screens have made a substantial impact in this space, being seen as a robust route for target identification and validation. However, drugs that target the proteins encoded by the genes identified in the CRISPR-Cas screen can also aid rapid validation of a particular pathway involved in a biological process of interest (such as differentiation state or drug resistance).

This webinar explores how CRISPR-Cas screens combined with in vitro cell panel drug screens in the immune cell space can aid the validation process ahead of moving into pre-clinical and clinical trials.

 

### Watch the Webinar

## Copyright 2020 Drug Discovery World. All Rights Reserved Privacy Policy & Cookies | Contact | Terms & Conditions